Preliminary results show a slim majority of voters in New Zealand rejected the country’s referendum on a proposed bill to legalize and regulate sales of adult-use cannabis, the country’s Electoral Commission announced today. However, the official outco…
Asia & Oceania Cannabis Industry & Marijuana Business News
New Zealand seeks proposals to educate doctors on medical cannabis
The New Zealand government has issued a request for proposals to provide the nation’s physicians with a primer on medical marijuana and its use as a medicine. The government hopes the resulting educational publication, or resource, will provide h…
Aurora Cannabis exits Australia’s Cann Group after $28M impairment charge
Alberta-based Aurora Cannabis sold off its stake in Australian medical marijuana company Cann Group, but the Canadian producer still sees promise in the Australian market. “We continue to see growth potential in this important market and will mai…
WHO cannabis recommendations still face uphill battle for adoption
The World Health Organization’s cannabis scheduling recommendations appeared to have limited support at a United Nations Commission on Narcotic Drugs (CND) “intersessional” meeting on Thursday in Vienna. That means the proposals still face an uphill ba…
New Zealand extends medical cannabis transition to avoid supply disruption
Medical cannabis suppliers in New Zealand have been given an extension on new product-assessment rules that were set to take effect this month. That development came to light in a Medicinal Cannabis Agency (MCA) communication sent to industry stakehold…
Australia approves record number of medical cannabis patients
Australia’s medical cannabis market continues to grow. In September, more than 6,000 patients were approved for medical marijuana treatment through the country’s Special Access Scheme (SAS) Category B pathway. That’s the highest monthly gain since 2016…
GW Pharmaceuticals cannabis drug gets regulatory OK in Australia
GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in treating seizures related to Lennox-Gastaut syndrome and Dravet syndrome for patients 2 and older. …